InnoCare Pharma announced on August 21 that the first patient was dosed in the registrational clinical trial of the company's independently developed novel BCL2 inhibitor Mesutoclax (ICP-248) for the treatment of mantle cell lymphoma (MCL) previously treated with BTK inhibitors.

Mesutoclax is a novel, oral, highly selective BCL2 inhibitor. BCL2 is a key regulatory protein in the apoptosis pathway, and its abnormal expression is associated with the development and progression of various hematological malignancies. Mesutoclax selectively inhibits BCL2, restoring the programmed cell death mechanism in tumor cells, thereby exerting its anti-tumor efficacy. This unique mechanism of action holds great potential for the treatment of MCL, chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and other indications. InnoCare Pharma is currently advancing clinical trials for these indications globally.

This registrational clinical trial is designed to evaluate the safety and efficacy of mesutoclax in patients with MCL who have previously been treated with a BTK inhibitor. MCL is an aggressive B-cell non-Hodgkin lymphoma with limited available treatment options.

Cui Jisong, co-founder, chairman, and CEO of InnoCare Pharma , stated that mesutoclax, as a key asset in the hematological malignancy field, is expected to bring new treatment hope to lymphoma patients. The company will continue to accelerate the clinical development of mesutoclax to provide more effective treatment options for patients worldwide.

https://finance.eastmoney.com/a/202508213490503051.html